var myjson = {
  "nodes": [
    {
      "name": "2::1072915200::68b06483eb42fd4f682c5195c48ab326f3dbf16d::1",
      "group": 0,
      "doi": "68b06483eb42fd4f682c5195c48ab326f3dbf16d",
      "publication_date": 1072915200,
      "path_index": 2,
      "is_original_author": "true",
      "title": "Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer.",
      "index": 0
    },
    {
      "name": "6::1072915200::68b06483eb42fd4f682c5195c48ab326f3dbf16d::1",
      "group": 0,
      "doi": "68b06483eb42fd4f682c5195c48ab326f3dbf16d",
      "publication_date": 1072915200,
      "path_index": 6,
      "is_original_author": "true",
      "title": "Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer.",
      "index": 1
    },
    {
      "name": "1::1104537600::bf8e36b271ef906338ae1a8c85a4bbda166c397f::1",
      "group": 0,
      "doi": "bf8e36b271ef906338ae1a8c85a4bbda166c397f",
      "publication_date": 1104537600,
      "path_index": 1,
      "is_original_author": "true",
      "title": "Changes in bone mineral density and body composition during initial and long-term gonadotropin-releasing hormone agonist treatment for prostate carcinoma.",
      "index": 2
    },
    {
      "name": "4::1104537600::bf8e36b271ef906338ae1a8c85a4bbda166c397f::1",
      "group": 0,
      "doi": "bf8e36b271ef906338ae1a8c85a4bbda166c397f",
      "publication_date": 1104537600,
      "path_index": 4,
      "is_original_author": "true",
      "title": "Changes in bone mineral density and body composition during initial and long-term gonadotropin-releasing hormone agonist treatment for prostate carcinoma.",
      "index": 3
    },
    {
      "name": "9::1104537600::bf8e36b271ef906338ae1a8c85a4bbda166c397f::1",
      "group": 0,
      "doi": "bf8e36b271ef906338ae1a8c85a4bbda166c397f",
      "publication_date": 1104537600,
      "path_index": 9,
      "is_original_author": "true",
      "title": "Changes in bone mineral density and body composition during initial and long-term gonadotropin-releasing hormone agonist treatment for prostate carcinoma.",
      "index": 4
    },
    {
      "name": "0::1136073600::b5063c7276e2c7a7763f0233c60fbe355451567f::1",
      "group": 0,
      "doi": "b5063c7276e2c7a7763f0233c60fbe355451567f",
      "publication_date": 1136073600,
      "path_index": 0,
      "is_original_author": "true",
      "title": "Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer.",
      "index": 5
    },
    {
      "name": "3::1136073600::b5063c7276e2c7a7763f0233c60fbe355451567f::1",
      "group": 0,
      "doi": "b5063c7276e2c7a7763f0233c60fbe355451567f",
      "publication_date": 1136073600,
      "path_index": 3,
      "is_original_author": "true",
      "title": "Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer.",
      "index": 6
    },
    {
      "name": "5::1136073600::b5063c7276e2c7a7763f0233c60fbe355451567f::1",
      "group": 0,
      "doi": "b5063c7276e2c7a7763f0233c60fbe355451567f",
      "publication_date": 1136073600,
      "path_index": 5,
      "is_original_author": "true",
      "title": "Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer.",
      "index": 7
    },
    {
      "name": "8::1136073600::b5063c7276e2c7a7763f0233c60fbe355451567f::1",
      "group": 0,
      "doi": "b5063c7276e2c7a7763f0233c60fbe355451567f",
      "publication_date": 1136073600,
      "path_index": 8,
      "is_original_author": "true",
      "title": "Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer.",
      "index": 8
    },
    {
      "name": "0::1167609600::7ba400225356a7d389f04e13e2d2506f40774fc8::0",
      "group": 0,
      "doi": "7ba400225356a7d389f04e13e2d2506f40774fc8",
      "publication_date": 1167609600,
      "path_index": 0,
      "is_original_author": "false",
      "title": "Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality.",
      "index": 9
    },
    {
      "name": "1::1167609600::7ba400225356a7d389f04e13e2d2506f40774fc8::0",
      "group": 0,
      "doi": "7ba400225356a7d389f04e13e2d2506f40774fc8",
      "publication_date": 1167609600,
      "path_index": 1,
      "is_original_author": "false",
      "title": "Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality.",
      "index": 10
    },
    {
      "name": "8::1167609600::7ba400225356a7d389f04e13e2d2506f40774fc8::0",
      "group": 0,
      "doi": "7ba400225356a7d389f04e13e2d2506f40774fc8",
      "publication_date": 1167609600,
      "path_index": 8,
      "is_original_author": "false",
      "title": "Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality.",
      "index": 11
    },
    {
      "name": "9::1167609600::7ba400225356a7d389f04e13e2d2506f40774fc8::0",
      "group": 0,
      "doi": "7ba400225356a7d389f04e13e2d2506f40774fc8",
      "publication_date": 1167609600,
      "path_index": 9,
      "is_original_author": "false",
      "title": "Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality.",
      "index": 12
    },
    {
      "name": "2::1199145600::45d710b9caa4d5252723b2e0854914c85ebe9649::0",
      "group": 0,
      "doi": "45d710b9caa4d5252723b2e0854914c85ebe9649",
      "publication_date": 1199145600,
      "path_index": 2,
      "is_original_author": "false",
      "title": "Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer.",
      "index": 13
    },
    {
      "name": "6::1199145600::45d710b9caa4d5252723b2e0854914c85ebe9649::0",
      "group": 0,
      "doi": "45d710b9caa4d5252723b2e0854914c85ebe9649",
      "publication_date": 1199145600,
      "path_index": 6,
      "is_original_author": "false",
      "title": "Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer.",
      "index": 14
    },
    {
      "name": "0::1230768000::a62b95f62b5cdf1cd3d1f05cc730441ee58016ab::0",
      "group": 0,
      "doi": "a62b95f62b5cdf1cd3d1f05cc730441ee58016ab",
      "publication_date": 1230768000,
      "path_index": 0,
      "is_original_author": "false",
      "title": "Reduced muscle strength and functional performance in men with prostate cancer undergoing androgen suppression: a comprehensive cross-sectional investigation",
      "index": 15
    },
    {
      "name": "1::1230768000::a62b95f62b5cdf1cd3d1f05cc730441ee58016ab::0",
      "group": 0,
      "doi": "a62b95f62b5cdf1cd3d1f05cc730441ee58016ab",
      "publication_date": 1230768000,
      "path_index": 1,
      "is_original_author": "false",
      "title": "Reduced muscle strength and functional performance in men with prostate cancer undergoing androgen suppression: a comprehensive cross-sectional investigation",
      "index": 16
    },
    {
      "name": "2::1230768000::a62b95f62b5cdf1cd3d1f05cc730441ee58016ab::0",
      "group": 0,
      "doi": "a62b95f62b5cdf1cd3d1f05cc730441ee58016ab",
      "publication_date": 1230768000,
      "path_index": 2,
      "is_original_author": "false",
      "title": "Reduced muscle strength and functional performance in men with prostate cancer undergoing androgen suppression: a comprehensive cross-sectional investigation",
      "index": 17
    },
    {
      "name": "3::1230768000::a62b95f62b5cdf1cd3d1f05cc730441ee58016ab::0",
      "group": 0,
      "doi": "a62b95f62b5cdf1cd3d1f05cc730441ee58016ab",
      "publication_date": 1230768000,
      "path_index": 3,
      "is_original_author": "false",
      "title": "Reduced muscle strength and functional performance in men with prostate cancer undergoing androgen suppression: a comprehensive cross-sectional investigation",
      "index": 18
    },
    {
      "name": "4::1230768000::a62b95f62b5cdf1cd3d1f05cc730441ee58016ab::0",
      "group": 0,
      "doi": "a62b95f62b5cdf1cd3d1f05cc730441ee58016ab",
      "publication_date": 1230768000,
      "path_index": 4,
      "is_original_author": "false",
      "title": "Reduced muscle strength and functional performance in men with prostate cancer undergoing androgen suppression: a comprehensive cross-sectional investigation",
      "index": 19
    },
    {
      "name": "6::1230768000::0dc232d9fc4c2c81d9bd8b08b6a3091b2c342075::0",
      "group": 0,
      "doi": "0dc232d9fc4c2c81d9bd8b08b6a3091b2c342075",
      "publication_date": 1230768000,
      "path_index": 6,
      "is_original_author": "false",
      "title": "Long-term effects of intermittent androgen suppression on testosterone recovery and bone mineral density: results of a 33-month observational study.",
      "index": 20
    },
    {
      "name": "0::1262304000::15eff5d128ac16a6b5c1d078f1107f5ab1e2f469::0",
      "group": 0,
      "doi": "15eff5d128ac16a6b5c1d078f1107f5ab1e2f469",
      "publication_date": 1262304000,
      "path_index": 0,
      "is_original_author": "false",
      "title": "Combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy for prostate cancer without bone metastases: a randomized controlled trial.",
      "index": 21
    },
    {
      "name": "1::1262304000::15eff5d128ac16a6b5c1d078f1107f5ab1e2f469::0",
      "group": 0,
      "doi": "15eff5d128ac16a6b5c1d078f1107f5ab1e2f469",
      "publication_date": 1262304000,
      "path_index": 1,
      "is_original_author": "false",
      "title": "Combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy for prostate cancer without bone metastases: a randomized controlled trial.",
      "index": 22
    },
    {
      "name": "2::1262304000::15eff5d128ac16a6b5c1d078f1107f5ab1e2f469::0",
      "group": 0,
      "doi": "15eff5d128ac16a6b5c1d078f1107f5ab1e2f469",
      "publication_date": 1262304000,
      "path_index": 2,
      "is_original_author": "false",
      "title": "Combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy for prostate cancer without bone metastases: a randomized controlled trial.",
      "index": 23
    },
    {
      "name": "3::1262304000::15eff5d128ac16a6b5c1d078f1107f5ab1e2f469::0",
      "group": 0,
      "doi": "15eff5d128ac16a6b5c1d078f1107f5ab1e2f469",
      "publication_date": 1262304000,
      "path_index": 3,
      "is_original_author": "false",
      "title": "Combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy for prostate cancer without bone metastases: a randomized controlled trial.",
      "index": 24
    },
    {
      "name": "4::1262304000::15eff5d128ac16a6b5c1d078f1107f5ab1e2f469::0",
      "group": 0,
      "doi": "15eff5d128ac16a6b5c1d078f1107f5ab1e2f469",
      "publication_date": 1262304000,
      "path_index": 4,
      "is_original_author": "false",
      "title": "Combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy for prostate cancer without bone metastases: a randomized controlled trial.",
      "index": 25
    },
    {
      "name": "7::1262304000::232f2036a94669bee54ef76a8f80005ef3e63052::1",
      "group": 0,
      "doi": "232f2036a94669bee54ef76a8f80005ef3e63052",
      "publication_date": 1262304000,
      "path_index": 7,
      "is_original_author": "true",
      "title": "Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology.",
      "index": 26
    },
    {
      "name": "7::1293840000::e0be7209a2f21f6fa2720d9b1694e1ffd52c6bc9::0",
      "group": 0,
      "doi": "e0be7209a2f21f6fa2720d9b1694e1ffd52c6bc9",
      "publication_date": 1293840000,
      "path_index": 7,
      "is_original_author": "false",
      "title": "Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials.",
      "index": 27
    },
    {
      "name": "8::1293840000::e0be7209a2f21f6fa2720d9b1694e1ffd52c6bc9::0",
      "group": 0,
      "doi": "e0be7209a2f21f6fa2720d9b1694e1ffd52c6bc9",
      "publication_date": 1293840000,
      "path_index": 8,
      "is_original_author": "false",
      "title": "Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials.",
      "index": 28
    },
    {
      "name": "9::1293840000::e0be7209a2f21f6fa2720d9b1694e1ffd52c6bc9::0",
      "group": 0,
      "doi": "e0be7209a2f21f6fa2720d9b1694e1ffd52c6bc9",
      "publication_date": 1293840000,
      "path_index": 9,
      "is_original_author": "false",
      "title": "Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials.",
      "index": 29
    },
    {
      "name": "5::1325376000::70ccf2c5788455177acd71d88e494c7db229cd9c::0",
      "group": 0,
      "doi": "70ccf2c5788455177acd71d88e494c7db229cd9c",
      "publication_date": 1325376000,
      "path_index": 5,
      "is_original_author": "false",
      "title": "Intermittent androgen suppression for rising PSA level after radiotherapy.",
      "index": 30
    },
    {
      "name": "6::1325376000::70ccf2c5788455177acd71d88e494c7db229cd9c::0",
      "group": 0,
      "doi": "70ccf2c5788455177acd71d88e494c7db229cd9c",
      "publication_date": 1325376000,
      "path_index": 6,
      "is_original_author": "false",
      "title": "Intermittent androgen suppression for rising PSA level after radiotherapy.",
      "index": 31
    },
    {
      "name": "5::1356998400::14c2b6f497d64d3feb829c8aa459ef4efe5cca05::0",
      "group": 0,
      "doi": "14c2b6f497d64d3feb829c8aa459ef4efe5cca05",
      "publication_date": 1356998400,
      "path_index": 5,
      "is_original_author": "false",
      "title": "Intermittent versus continuous cyproterone acetate in bone metastatic prostate cancer: results of a randomized trial",
      "index": 32
    },
    {
      "name": "6::1356998400::14c2b6f497d64d3feb829c8aa459ef4efe5cca05::0",
      "group": 0,
      "doi": "14c2b6f497d64d3feb829c8aa459ef4efe5cca05",
      "publication_date": 1356998400,
      "path_index": 6,
      "is_original_author": "false",
      "title": "Intermittent versus continuous cyproterone acetate in bone metastatic prostate cancer: results of a randomized trial",
      "index": 33
    },
    {
      "name": "7::1356998400::14c2b6f497d64d3feb829c8aa459ef4efe5cca05::0",
      "group": 0,
      "doi": "14c2b6f497d64d3feb829c8aa459ef4efe5cca05",
      "publication_date": 1356998400,
      "path_index": 7,
      "is_original_author": "false",
      "title": "Intermittent versus continuous cyproterone acetate in bone metastatic prostate cancer: results of a randomized trial",
      "index": 34
    },
    {
      "name": "8::1356998400::14c2b6f497d64d3feb829c8aa459ef4efe5cca05::0",
      "group": 0,
      "doi": "14c2b6f497d64d3feb829c8aa459ef4efe5cca05",
      "publication_date": 1356998400,
      "path_index": 8,
      "is_original_author": "false",
      "title": "Intermittent versus continuous cyproterone acetate in bone metastatic prostate cancer: results of a randomized trial",
      "index": 35
    },
    {
      "name": "9::1356998400::14c2b6f497d64d3feb829c8aa459ef4efe5cca05::0",
      "group": 0,
      "doi": "14c2b6f497d64d3feb829c8aa459ef4efe5cca05",
      "publication_date": 1356998400,
      "path_index": 9,
      "is_original_author": "false",
      "title": "Intermittent versus continuous cyproterone acetate in bone metastatic prostate cancer: results of a randomized trial",
      "index": 36
    },
    {
      "name": "0::1420070400::dba56b1d8b91142cc772b04655797d0d0f2fc532::1",
      "group": 0,
      "doi": "dba56b1d8b91142cc772b04655797d0d0f2fc532",
      "publication_date": 1420070400,
      "path_index": 0,
      "is_original_author": "true",
      "title": "Adverse effects of androgen deprivation therapy and strategies to mitigate them.",
      "index": 37
    },
    {
      "name": "1::1420070400::dba56b1d8b91142cc772b04655797d0d0f2fc532::1",
      "group": 0,
      "doi": "dba56b1d8b91142cc772b04655797d0d0f2fc532",
      "publication_date": 1420070400,
      "path_index": 1,
      "is_original_author": "true",
      "title": "Adverse effects of androgen deprivation therapy and strategies to mitigate them.",
      "index": 38
    },
    {
      "name": "2::1420070400::dba56b1d8b91142cc772b04655797d0d0f2fc532::1",
      "group": 0,
      "doi": "dba56b1d8b91142cc772b04655797d0d0f2fc532",
      "publication_date": 1420070400,
      "path_index": 2,
      "is_original_author": "true",
      "title": "Adverse effects of androgen deprivation therapy and strategies to mitigate them.",
      "index": 39
    },
    {
      "name": "3::1420070400::dba56b1d8b91142cc772b04655797d0d0f2fc532::1",
      "group": 0,
      "doi": "dba56b1d8b91142cc772b04655797d0d0f2fc532",
      "publication_date": 1420070400,
      "path_index": 3,
      "is_original_author": "true",
      "title": "Adverse effects of androgen deprivation therapy and strategies to mitigate them.",
      "index": 40
    },
    {
      "name": "4::1420070400::dba56b1d8b91142cc772b04655797d0d0f2fc532::1",
      "group": 0,
      "doi": "dba56b1d8b91142cc772b04655797d0d0f2fc532",
      "publication_date": 1420070400,
      "path_index": 4,
      "is_original_author": "true",
      "title": "Adverse effects of androgen deprivation therapy and strategies to mitigate them.",
      "index": 41
    },
    {
      "name": "5::1420070400::dba56b1d8b91142cc772b04655797d0d0f2fc532::1",
      "group": 0,
      "doi": "dba56b1d8b91142cc772b04655797d0d0f2fc532",
      "publication_date": 1420070400,
      "path_index": 5,
      "is_original_author": "true",
      "title": "Adverse effects of androgen deprivation therapy and strategies to mitigate them.",
      "index": 42
    },
    {
      "name": "6::1420070400::dba56b1d8b91142cc772b04655797d0d0f2fc532::1",
      "group": 0,
      "doi": "dba56b1d8b91142cc772b04655797d0d0f2fc532",
      "publication_date": 1420070400,
      "path_index": 6,
      "is_original_author": "true",
      "title": "Adverse effects of androgen deprivation therapy and strategies to mitigate them.",
      "index": 43
    },
    {
      "name": "7::1420070400::dba56b1d8b91142cc772b04655797d0d0f2fc532::1",
      "group": 0,
      "doi": "dba56b1d8b91142cc772b04655797d0d0f2fc532",
      "publication_date": 1420070400,
      "path_index": 7,
      "is_original_author": "true",
      "title": "Adverse effects of androgen deprivation therapy and strategies to mitigate them.",
      "index": 44
    },
    {
      "name": "8::1420070400::dba56b1d8b91142cc772b04655797d0d0f2fc532::1",
      "group": 0,
      "doi": "dba56b1d8b91142cc772b04655797d0d0f2fc532",
      "publication_date": 1420070400,
      "path_index": 8,
      "is_original_author": "true",
      "title": "Adverse effects of androgen deprivation therapy and strategies to mitigate them.",
      "index": 45
    },
    {
      "name": "9::1420070400::dba56b1d8b91142cc772b04655797d0d0f2fc532::1",
      "group": 0,
      "doi": "dba56b1d8b91142cc772b04655797d0d0f2fc532",
      "publication_date": 1420070400,
      "path_index": 9,
      "is_original_author": "true",
      "title": "Adverse effects of androgen deprivation therapy and strategies to mitigate them.",
      "index": 46
    },
    {
      "name": "5::1451606400::c51662ee28b449c14005be6422f92e91cbba5248::0",
      "group": 0,
      "doi": "c51662ee28b449c14005be6422f92e91cbba5248",
      "publication_date": 1451606400,
      "path_index": 5,
      "is_original_author": "false",
      "title": "Intermittent Versus Continuous Androgen Deprivation Therapy in Patients with Relapsing or Locally Advanced Prostate Cancer: A Phase 3b Randomised Study (ICELAND).",
      "index": 47
    },
    {
      "name": "6::1451606400::c51662ee28b449c14005be6422f92e91cbba5248::0",
      "group": 0,
      "doi": "c51662ee28b449c14005be6422f92e91cbba5248",
      "publication_date": 1451606400,
      "path_index": 6,
      "is_original_author": "false",
      "title": "Intermittent Versus Continuous Androgen Deprivation Therapy in Patients with Relapsing or Locally Advanced Prostate Cancer: A Phase 3b Randomised Study (ICELAND).",
      "index": 48
    },
    {
      "name": "7::1451606400::c51662ee28b449c14005be6422f92e91cbba5248::0",
      "group": 0,
      "doi": "c51662ee28b449c14005be6422f92e91cbba5248",
      "publication_date": 1451606400,
      "path_index": 7,
      "is_original_author": "false",
      "title": "Intermittent Versus Continuous Androgen Deprivation Therapy in Patients with Relapsing or Locally Advanced Prostate Cancer: A Phase 3b Randomised Study (ICELAND).",
      "index": 49
    },
    {
      "name": "8::1451606400::c51662ee28b449c14005be6422f92e91cbba5248::0",
      "group": 0,
      "doi": "c51662ee28b449c14005be6422f92e91cbba5248",
      "publication_date": 1451606400,
      "path_index": 8,
      "is_original_author": "false",
      "title": "Intermittent Versus Continuous Androgen Deprivation Therapy in Patients with Relapsing or Locally Advanced Prostate Cancer: A Phase 3b Randomised Study (ICELAND).",
      "index": 50
    },
    {
      "name": "9::1451606400::c51662ee28b449c14005be6422f92e91cbba5248::0",
      "group": 0,
      "doi": "c51662ee28b449c14005be6422f92e91cbba5248",
      "publication_date": 1451606400,
      "path_index": 9,
      "is_original_author": "false",
      "title": "Intermittent Versus Continuous Androgen Deprivation Therapy in Patients with Relapsing or Locally Advanced Prostate Cancer: A Phase 3b Randomised Study (ICELAND).",
      "index": 51
    }
  ],
  "links": [
    {
      "source": 37,
      "target": 21,
      "value": 1,
      "index": 0
    },
    {
      "source": 21,
      "target": 15,
      "value": 1,
      "index": 1
    },
    {
      "source": 15,
      "target": 9,
      "value": 1,
      "index": 2
    },
    {
      "source": 9,
      "target": 5,
      "value": 1,
      "index": 3
    },
    {
      "source": 38,
      "target": 22,
      "value": 1,
      "index": 4
    },
    {
      "source": 22,
      "target": 16,
      "value": 1,
      "index": 5
    },
    {
      "source": 16,
      "target": 10,
      "value": 1,
      "index": 6
    },
    {
      "source": 10,
      "target": 2,
      "value": 1,
      "index": 7
    },
    {
      "source": 39,
      "target": 23,
      "value": 1,
      "index": 8
    },
    {
      "source": 23,
      "target": 17,
      "value": 1,
      "index": 9
    },
    {
      "source": 17,
      "target": 13,
      "value": 1,
      "index": 10
    },
    {
      "source": 13,
      "target": 0,
      "value": 1,
      "index": 11
    },
    {
      "source": 40,
      "target": 24,
      "value": 1,
      "index": 12
    },
    {
      "source": 24,
      "target": 18,
      "value": 1,
      "index": 13
    },
    {
      "source": 18,
      "target": 6,
      "value": 1,
      "index": 14
    },
    {
      "source": 41,
      "target": 25,
      "value": 1,
      "index": 15
    },
    {
      "source": 25,
      "target": 19,
      "value": 1,
      "index": 16
    },
    {
      "source": 19,
      "target": 3,
      "value": 1,
      "index": 17
    },
    {
      "source": 42,
      "target": 47,
      "value": 1,
      "index": 18
    },
    {
      "source": 47,
      "target": 32,
      "value": 1,
      "index": 19
    },
    {
      "source": 32,
      "target": 30,
      "value": 1,
      "index": 20
    },
    {
      "source": 30,
      "target": 7,
      "value": 1,
      "index": 21
    },
    {
      "source": 43,
      "target": 48,
      "value": 1,
      "index": 22
    },
    {
      "source": 48,
      "target": 33,
      "value": 1,
      "index": 23
    },
    {
      "source": 33,
      "target": 31,
      "value": 1,
      "index": 24
    },
    {
      "source": 31,
      "target": 20,
      "value": 1,
      "index": 25
    },
    {
      "source": 20,
      "target": 14,
      "value": 1,
      "index": 26
    },
    {
      "source": 14,
      "target": 1,
      "value": 1,
      "index": 27
    },
    {
      "source": 44,
      "target": 49,
      "value": 1,
      "index": 28
    },
    {
      "source": 49,
      "target": 34,
      "value": 1,
      "index": 29
    },
    {
      "source": 34,
      "target": 27,
      "value": 1,
      "index": 30
    },
    {
      "source": 27,
      "target": 26,
      "value": 1,
      "index": 31
    },
    {
      "source": 45,
      "target": 50,
      "value": 1,
      "index": 32
    },
    {
      "source": 50,
      "target": 35,
      "value": 1,
      "index": 33
    },
    {
      "source": 35,
      "target": 28,
      "value": 1,
      "index": 34
    },
    {
      "source": 28,
      "target": 11,
      "value": 1,
      "index": 35
    },
    {
      "source": 11,
      "target": 8,
      "value": 1,
      "index": 36
    },
    {
      "source": 46,
      "target": 51,
      "value": 1,
      "index": 37
    },
    {
      "source": 51,
      "target": 36,
      "value": 1,
      "index": 38
    },
    {
      "source": 36,
      "target": 29,
      "value": 1,
      "index": 39
    },
    {
      "source": 29,
      "target": 12,
      "value": 1,
      "index": 40
    },
    {
      "source": 12,
      "target": 4,
      "value": 1,
      "index": 41
    }
  ]
}